8h agoInvesting.com MarketsBEARISH 38General
Why is Tango Therapeutics stock sliding today?
Why is Tango Therapeutics stock sliding today?
Archived explainer. For the current picture see today's TNGX page.
Why Is TANGO THERAPEUTICS I (TNGX) Stock Down Today?
By the Top Tier Newswire AI Desk · October 23, 2026 at 9:43 AM ET · reviewed against 5 wire stories
TANGO THERAPEUTICS I (TNGX) is down -15.61% in the latest session. Our newswire has captured 5 stories on TNGX across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Tango Therapeutics stock (TNGX) fell 15.61% to $23.57 on Friday. The decline occurred despite the company reporting positive Phase 1/2 data for its vopimetostat and daraxonrasib combination in pancreatic cancer.
What Happened
Tango Therapeutics disclosed updated Phase 1/2 results showing an 82% objective response rate and an 88% nine-month progression-free survival rate in 22 efficacy-evaluable patients with second or third-line MTAP-deleted and RAS-mutant pancreatic cancer. The company plans to start a Phase 3 trial in the first half of 2027. A Form 8-K filed on October 23, 2026, included the data under Regulation FD disclosure. William Blair initiated coverage on the stock with an Outperform rating. The stock had previously beaten expectations for the combination using Revolution Medicines' newly approved drug.
What The Data Shows
The session opened at $28.82, a 3.2% gap up from the prior close of $27.93. The stock hit a session high of $29.75 at 7:00 AM ET before dropping to a session low of $22.94 at 7:15 AM ET. Volume stood at 2.1 million shares, which is 0.7 times the three-month daily average. The company has a market cap of $4.5 billion and is unprofitable with a trailing twelve-month EPS of -0.91. Revenue grew 121.5% over the trailing twelve months, while the net margin was -229.9%. The stock has a beta of 1.17 and a 52-week range of $6.69 to $34.39. Over the last eight sessions, the stock moved up 4.3% from $25.85 to $26.95. On October 23, the stock printed one fresh 52-week high and five fresh 52-week lows. Recent insider activity includes four sells totaling $2.2 million over the last 90 days, with no buys. The most recent sale was filed on October 5, 2026.
What To Watch
Investors will monitor the planned Phase 3 trial start in the first half of 2027 and the company's upcoming earnings reports.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TNGX by the numbers
Last: $23.57Session: -15.61%7 sessions: +4.27%Coverage: 5 stories / 4 sourcesAI sentiment: 53/100 (mixed)Mkt cap: $4.5B52w: $6.69 to $34.39
The headlines behind the move
8h agoInvesting.com MarketsBEARISH 38General
Tango Therapeutics stock falls despite positive cancer trial data
Tango Therapeutics stock falls despite positive cancer trial data
8h agoMarketChameleonBULLISH 74Product/PR
Tango’s vopimetostat combo posts 82% response rate in heavily pretreated pancreatic cancer, setting up a planned Phase 3 start in 1H 2027 October 23, 2026
Tango Therapeutics reported updated Phase 1/2 data showing an 82% objective response rate and an 88% 9-month progression-free survival rate in 22 efficacy-evaluable patients with 2L/3L MTAP-deleted/RAS-mutant pancreatic cancer treated with vopimetostat plus daraxonrasib. Following FDA interactions, the company said it expects to initiate a global, randomized registrational Phase 3 study in front-line MTAP-deleted PDAC in the first half of 2027, with ORR and PFS as dual primary endpoints.
9h agoSEC 8-KNEUTRAL 50General
Tango Therapeutics, Inc. (TNGX) files 8-K
Filed: 2026-10-23 AccNo: 0001193125-26-429423 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
9h agoInvestors.comBULLISH 64Product/PR
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TNGX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TNGX move explainers: 2026-10-23